Thought Leadership | Fish & Richardson

Diversity, Equity & Inclusion

Pro Bono & Social Responsibility

Legal Operations

Legal Project Management

Knowledge Management

Legal Technology Services

Patent Litigation

Trademark, Copyright & Media Litigation

Trade Secret Litigation

Standard Essential Patents

Chancery & Corporate Governance

<p><em>Inter Partes </em>Review</p>

Post-Grant Review

<p><em>Ex Parte</em> Reexamination</p>

Supplemental Examination

Patent Prosecution

Strategic Patent Counseling & Opinions

Patent Portfolio Management

Unitary Patent & Unified Patent Court

IP Licensing, Transactions & Agreements

Trademark & Copyright Counseling & Prosecution

Strategic Counseling, Registration & Opinions

Advertising & Marketing

Domain Names & Internet

TTAB Oppositions & Cancellations

Digital Millennium Copyright Act

Transactions & Agreements

Regulatory & Government Affairs

Communications & Spectrum Regulation

Drug & Medical Device Regulation

mHealth & Telemedicine

Privacy & Data Security

Electrical & Computer Technology

Software & Internet

Consumer Electronics

Artificial Intelligence

Digital Media & E-Commerce

Financial, Business & FinTech Services

Telecommunications

Energy & Chemicals

Biotech & Diagnostics

Medical Devices

Pharmaceuticals

Academic Research & Medical Centers

Transportation, Aerospace & Defense

Autonomous Vehicles

Thought Leadership

IP Law Essentials

Post-Grant Annual Reports

Search results

Blog | February 07, 2017

Minnesota Patent Litigation Wrap-Up — January 2017

Blog | January 05, 2017

Confidentiality in BPCIA Cases

Q&A | January 03, 2017

Q&A with Michael McKeon: ITC's Powerful Patent Remedies

Blog | December 23, 2016

The First Amendment Does Not Protect All Off-Label Drug Promotion

Blog | December 23, 2016

DDE denies request to strike lost profits opinion re non-patented items; addresses test data admissibility

Article | December 14, 2016

How to build Daubert-proof patent damages cases

Blog | December 07, 2016

Survey of the Safe Harbor in the United States and Europe

Blog | November 22, 2016

Alert: Federal Circuit Narrows the Types of Patents That Can Be Challenged in a Covered Business Method Review

Blog | October 20, 2016

Biogen Dodges IPR Bullet on Key Tysabri® Patents

Blog | October 13, 2016

Federal Circuit Affirms the Dismissal of a Complaint That Insufficiently Pleaded Joint Infringement

Blog | October 07, 2016

Amgen Appeals Loss of Neulasta® and Neupogen® Litigation

Blog | October 06, 2016

EDTX denies exclusion of settlement license and "real estate" apportionment